THC Farmaceuticals, Inc. Acquires Controlling Interest in G.K. Manufacturing from Cannabis Sativa, Inc.

May 04, 2021 10:39 ET | Source: CBDual Biotechnology Corp

THOUSAND OAKS, CA, May 04, 2021 (GLOBE NEWSWIRE) — CBDual Biotechnology Corp’s parent company, THC Farmaceuticals, Inc (OTC: CBDG), developer of a unique line of premium CBD based oral health products as well as Dr. Rubin’s Dental Anxiety Pills, today announced that it had reached a binding agreement to acquire a controlling ownership interest in G.K. Manufacturing from Cannabis Sativa, Inc., (OTCQB: CBDS).

“This acquisition positions us to rapidly expand our CBD product lines due to G.K.’s ability to produce up to 12 million product units per month while being conveniently located in Anaheim, California,” said veteran manufacturing lawyer and Vice President of CBDG Mark Grossman.

With the Acquisition of G.K. Manufacturing, The Company strengthens its capabilities to supply U.S. domestic markets with an expanded product offerings, including a new line of dental care-related products. Additionally, the Acquisition provides an entry into the U.S. market with innovative and leading CBD health and wellness brands, including an established manufacturing and distribution platform.

G.K. Manufacturing is a Southern California contract manufacturing, co-packing, and white label company, producing a wide range of the highest quality, lab-tested CBD products, including edibles, tinctures, drinks, and topicals. The Acquisition includes multiple brands such as the well-established Ganja Juice brand (ganja-juice.com) and Murray & Rocco’s CBD infused pet line. G.K. Manufacturing has pending nationwide and global sales contracts with companies in the U.S., UK, France, and Spain. “We are excited to acquire a majority interest in a company that has strong co-packing and white label opportunities in the CBD industry. The multitude of new concepts and brand ideas under development by G.K. Manufacturing and CBDUAL Biotechnology will help to drive sales in the coming periods. The acquisition positions CBDG to become a premium developer and manufacturer of new products in the booming CBD marketplace.” said Dr. Greg Rubin, Founder, and CEO of CBDUAL Biotechnology.

Recent Grand View Research indicated that: The global CBD oil and CBD consumer health market size was valued at USD 20.3 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 25.6% from 2020 to 2027. Increasing the adoption of cannabidiol (CBD) and infused products for various medical and wellness purposes is the key factor driving the market’s growth. In addition, favorable government regulations and increasing consumer awareness and demand for cannabidiol due to its health benefits further increase its adoption. Furthermore, CBD consumer health products are also gaining significant acceptance owing to their health benefits without any psychoactive effects. Increasing awareness regarding health benefits offered by cannabidiol-infused products has led to an increase in a consumer pool willing to buy these products.

Moreover, the increasing product options for consumers, such as dietary supplements, analgesics, edibles, topicals, oils, and capsules, are driving the market. Growing demand for cannabidiol in pharmaceutical formulations owing to its healing properties is expected to boost the demand for the product in the pharmaceutical industry. Other factors contributing to the increase in demand for CBD oil include rising consumer preference toward oil as a product category, the surge in demand for full-spectrum products, and many companies entering into bulk as well as finished product business. This segment is anticipated to register a lucrative growth in the forthcoming years owing to the increase in demand for cannabidiol from various end-user industries such as pharmaceuticals, food and beverage, and personal care and cosmetics, which is expected to trigger market growth.

CURRENT STATUS ON OTC MARKETS

The Company has published in the past its fiscal year ending September 30, 2020, annual report on its website here: http://cbdg.com/investor-relations/financials/ However, moving forward, the Company will resume publishing its disclosures on OTC Markets in order to provide a greater level of transparency and access to the markets as well as meeting their June 30, 2021, deadline for alternative reporting.

ABOUT GK MANUFACTURING

GK Manufacturing & Packaging, Inc. (“G.K.”) http://gkmanufacturinginc.com, leases a 16,364 square foot building in Anaheim, CA. G.K.’s facility is FDA Registered, ISO 9001 Compliant, CGMP Compliant, and Halal/Kosher Certified. The facility is a free-standing building with full HVAC systems, state-of-the-art security and is capable of producing up to 12 million product units per month.

GKMP offers a full-service co-packing solution for CBD brands with in-house formulations and over 400 product SKUs, as well as label design, in-house printing, and in-house media (offering photo, video, and content creation).

G.K. Manufacturing has been formulating and manufacturing for more than a dozen years, specializing in unique and specialty products, including topicals and beverages. White label services ranging from expert formulation and mixology to packaging and design, along with fulfillment including online orders, warehousing, and drop-shipping, are all offered by G.K. For information, visit the contact page at http://gkmanufacturinginc.com/.

About Cannabis Sativa, Inc.

Cannabis Sativa, Inc. (“CBDS”) is engaged in the licensing of cannabis-related intellectual property, marketing and branding for cannabis-based products and services, operation of cannabis-related technology services, and ancillary business activities. CBDS licenses the “hi” and “White Rabbit” brands, holds a U.S. patent on the Ecuadorian Sativa strain of Cannabis, a U.S. Patent for a marijuana lozenge, and operates its primary subsidiary PrestoDoctor® (https://prestodoctor.com).

About CBDual Biotechnology Corp.

THC Farmaceuticals, Inc.: (OTC: CBDG), through its subsidiary, CBDual Biotechnology Corp., is a pharmaceutical start-up company that focuses on developing products based on cannabidiol (CBD) and/or Tetrahydrocannabinol (THC). The Company’s facility is located in Southern California. We provide easy access for patients to participate in clinical trials of new medical cannabis medications, therapies, and products. CBDual Biotechnology Corp is a privately held U.S. Based Biotechnology company with proprietary technology for enhanced oral delivery of bioactive cannabinoids. This technology promotes overall oral health due to the higher effectiveness of the delivery methodology. The Company was founded in 2016 and is headquartered in California, with its R&D in the U.S. and Israel.

On November 26, 2018, the Company took steps to become the world’s first public Company to enter the magic mushroom space, subsequently forming its subsidiary, Medical Mushrooms Ltd.

Recently the Company has begun research on psilocybin for the purpose of conducting clinical trials involving the combination of genetic testing and micro-dosing of psilocybin formulations. We are well-positioned to begin clinical trials involving psilocybin since we have already cleared a path for cannabis-related clinical trials. The purpose of this division is to engage in advanced research of the growing niche of pharmaceutical-grade medicinal mushrooms, including psychedelics. The Company has registered the following domain names:

www.psycomagic.info

www.magicpharmaceuticals.com

www.psycomagic.com

For additional information, visit the Company’s website: http://cbdual.com/ and http://cbdg.com/.

Follow us on Twitter @THCFarma and @CBDualBiotech.

Forward-Looking Statements:

This press release contains “forward-looking statements.” Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with the Securities and Exchange Commission, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

SOURCE: CBDual Biotechnology Corp.

Contact:

tel: 805-978-5609

DR. RUBIN’S ANXIETY PILL MADE OF CANNABIS TO HIT THE MARKET NEXT WEEK

December 07, 2020 13:48 ET | Source: CBDual Biotechnology Corp.


Thousand Oaks, CA, Dec. 07, 2020 (GLOBE NEWSWIRE) — CBDual Biotechnology Corp., a subsidiary of THC Farmaceuticals, Inc (OTC PINK: CBDG) developer of a unique line of premium CBD based oral health products, today announced that it had completed the research and development of a groundbreaking new CBD based dental anxiety formulation that will be available next week for purchase on CBDUAL’S website and participating dental offices.

Research shows that cannabidiol (CBD) can help ameliorate severe medical symptoms from multiple sclerosis, cancer, Parkinson’s, Alzheimer’s, anxiety, and depression.

CBD products have been of interest in treating both socially and physically-based anxiety disorders. The FDA approved the use of cannabidiol in treating epilepsy. A recent clinical trial has shown that CBD can effectively reduce anxiety.

The Permanente Journal published a study reporting that 79% of participants experienced a reduction in anxiety after ingesting cannabinoids. Hence, these preliminary results on CBD’s positive effects have caused mental health advocates to consider CBDs for their anti-anxiety properties.

Even though the way CBD works to treat anxiety isn’t fully understood, it hasn’t stopped millions of people in need of symptom relief from using CBDs. It is reported in a 2019 Gallup Poll that 14% of Americans use CBD.

Research indicates that the prevalence of dental anxiety in the US is about 10-20 percent of patients visiting dental offices. Regression analysis revealed several factors associated with dental anxiety, the most significant of which are: unfavorable attitude towards and fear that dentists will cause pain. Dentists are aware of these and other factors when assessing dental anxiety in their patient populations. They are looking for alternative ways to reduce dental anxiety during visits.

The American Dental Association (ADA) names fear and dental anxiety as one of the reasons people avoid proper dental care. Also, 1 in 5 adults experience anxiety due to the health condition of their mouth and teeth, 22% of patients are afraid of dentists. This is a severe problem since the health of one’s mouth is paramount to the general; overall, the physical and mental health of each individual.

There are currently over 200,000 practicing dentists in the United States. Each dentist is seeing approximately 3500 patient/visits per year. The Company conservatively estimates the potential market size for its CBD dental anxiety products could to be $70,000,000 per year.

“As a leader in the field of CBD based dental and oral hygiene formulations, our primary goal is to research and manufacture CBD products made from plant-derived, organically-grown US hemp from trusted growers,” says Dr. Greg Rubin, CEO of CBDUAL Biotechnology Corp.

For more information and to preorder, please email: [email protected]

ANNUAL REPORT

THC Farmaceuticals Inc (OTC PINK: CBDG)   has published its fiscal year ending September 30, 2020, annual report. Under new SEC rules, OTC Pink companies may now publish their financial statements on their websites in lieu of publication on the OTCMarkets.com website and therefore, until further notice, CBDG will publish its financial statements here: http://cbdg.com/investor-relations/financials/

About CBDual Biotechnology Corp.

THC Farmaceuticals, Inc.: (OTC: CBDG) through its subsidiary, CBDual Biotechnology Corp., is a pharmaceutical start-up company focuses on developing products based on cannabidiol (CBD) and/or Tetrahydrocannabinol (THC). The Company’s facility is located in Southern California. We provide easy access for patients to participate in clinical trials of new medical cannabis medications, therapies, and products. CBDual Biotechnology Corp is a privately held, US Based Biotechnology company with proprietary technology for enhanced oral delivery of bioactive cannabinoids . This technology promotes overall oral health due to the higher effectiveness of the delivery methodology. The Company was founded in 2016 and is headquartered in California, with its R&D in the US and Israel.

On November 26, 2018, the Company took its first steps to become the world’s first public Company to enter the magic mushroom space, subsequently forming its subsidiary, Medical Mushrooms  Ltd.

Recently the Company has begun research on psilocybin for the purpose of conducting clinical trials involving the combination of genetic testing and micro-dosing of psilocybin formulations. We are well-positioned to begin clinical trials involving psilocybin since we have already cleared a path for cannabis-related clinical trials. The purpose of this division is to engage in advanced research of the growing niche of pharmaceutical-grade medicinal mushrooms, including psychedelics. The Company has registered the following domain names:

www.psycomagic.info

www.magicpharmaceuticals.com

www.psycomagic.com

For additional information, visit the Company’s website: http://cbdual.com/ and http://cbdg.com/

Follow us on Twitter @THCFarma and @CBDualBiotech.

Forward-Looking Statements:

This press release contains “forward-looking statements.” Although the forward-looking statements in this release reflect the good faith judgment of management, forward-looking statements are inherently subject to known and unknown risks and uncertainties that may cause actual results to be materially different from those discussed in these forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by us in our reports filed with the Securities and Exchange Commission, including the risk factors that attempt to advise interested parties of the risks that may affect our business, financial condition, results of operation and cash flows. If one or more of these risks or uncertainties materialize, or if the underlying assumptions prove incorrect, our actual results may vary materially from those expected or projected. Readers are urged not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.

SOURCE: CBDual Biotechnology Corp.

Mike Gravel and His Online Teens Want Weed in the Constitution

It’s an unconventional approach befitting of an unconventional presidential candidate.

Billy Binion | 7.12.2019 1:45 PM

Webp.net-resizeimage (4)

(Mike Gravel, Twitter)

Most people would be hard-pressed to remember every candidate who showed up at last month’s two-night Democratic presidential debate, must less the candidates who didn’t appear. But one contender who did not make the qualifying threshold was Mike Gravel, the 89-year-old former Alaskan senator. And all things considered, Gravel is pretty memorable: What he lacks in name recognition, he makes up for with an unorthodox and deliberately outrageous approach to politics. (His campaign, for example, is being run by two teenagers.)

Now the former senator is proposing a constitutional amendment to remove marijuana as a Schedule 1 drug, thus legalizing it recreationally on the federal level. It’s an unconventional approach to drug reform befitting of an unconventional presidential candidate, but Gravel argues that it would be the easiest way given the current congressional gridlock.

“Congress hasn’t done anything at this point in time, and it’s tough to realize whether we’re looking at another year, two years,” he tells Reason. “From my experience in the Congress, they could pretty well screw it up, and this is already unbelievably screwed up. We could immediately get a law passed in the next 30 days, but we’ve been waiting 30 days for the past three years.”

In times past, constitutional amendments have been implemented with a two-thirds vote of approval in both the House and the Senate, which then must be ratified by three-fourths of the states. But Gravel acknowledges that his plan would be a near-impossible sell if Republicans maintain control of the Senate. In that case, he says, he would take advantage of a second avenue—a constitutional convention—in which 34 states would need to gather on their own accord and agree to adopt the amendment. That route has never before been used.

Gravel compares the harmful effects of marijuana bans to the harmful effects of alcohol Prohibition. And Prohibition, he reminds us, was repealed by constitutional amendment—though only because it started with one. The 21st Amendment nullified the 18th.

“It’s an option is really what I’m saying,” says Gravel. The candidate doesn’t rule out the chance that Congress could act—in fact, he muses that the pressure of a convention could force lawmakers to come together. But he doubts that would happen. And even it if does, he worries about the poison pills and bargaining chips that could pollute the legislation.

However it pans out, Gravel sees federal action as a necessary way forward. The current state-by-state approach is a “mess,” he says, “promulgated by the fact that the federal Damocles hangs over” their heads. (When former Attorney General Jeff Sessions took office, he threatened to crack down on marijuana using federal jurisdiction, even in states that legalized it.) Gravel also rails against sky-high pot taxes, which he says have sometimes “been so horrendous that people have stayed with the underground supply rather than the legal supply.” Schedule 1 substances are subject to heavy federal income taxation, as the government prohibits (fully legal) state businesses of the weed variety from deducting a slew of business expenses. So his amendment also declares that the drug will be regulated like alcohol and tobacco.

While Gravel limits the proposed amendment to marijuana, he supports the decriminalization of all drugs. “We treat all of these drugs as criminal problems,” he explains. “They’re not. They’re public health problems.” He speaks fondly of the approach taken by Portugal, a fairly conservative country that in 2001 decriminalized all illicit substances, including heroin and cocaine. Drug trafficking there is still a criminal offense, but those caught with less than a 10-day supply get no more than a slap on the wrist—a fine, for instance. The problem is otherwise considered a medical one, where individuals meet with a local commission to discuss possible treatment options. The method has been widely successful, with the nation seeing a decrease in overdoses, drug-related crime, HIV infections, and adolescent drug use.

Gravel hopes his amendment will help put the U.S. on track to something like the Portuguese model. “Once you see the success of cannabis and addressing that problem in society, then society matures with these experiences and reacts differently,” the former senator says. “If we were to succeed with this, then I think it would really lead to a legislative approach.”

Although the campaign recently announced that it might be coming to an end in the near future, it received new life with a fundraising plea made by Marianne Williamson—a fellow contender for the Democratic nomination—on Gravel’s behalf, putting him in striking distance of the 65,000-donor threshold required to make the July debates. (At the time of this writing, he is less than 3,000 short.) If it doesn’t happen, he concedes that he won’t be heartbroken. His campaign, he says, was less about ascending to the Oval Office and more about starting a conversation about the issues—something that only became a reality when David Oks and Henry Williams, the two teens at the heart of his effort, urged him to run.

“Do you realize how old I am?” he asked the boys when they approached him.

“Doesn’t make any difference,” they replied. “It’s the positions you have on the issues that are so vital to communicate.”

In addition to drug reform, Gravel wants to cut military spending in half. He also supports single-payer health care and calls for the abolition of private insurance companies.

The deadline to qualify for the next Democratic debate is July 16. If Gravel makes it, his debate appearance will represent a major shift in his campaign—and not just because he’ll have a big platform for an evening. Up until now, he has not left his house in the pursuit of his 2020 ambitions. And until the next debate, he plans to stay put.

“No party’s gonna carry me other than these kids,” he says, referring to Oks and Williams. “But I’m gonna have a patio campaign. I’m gonna sit on my patio, and see what happens.”

Article First Published on Gravel

Sign Up For Our Newsletter